<?xml version='1.0' encoding='utf-8'?>
<document id="23884207"><sentence text="Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content." /><sentence text="Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR) and is increasingly being used in transplantation and cancer therapies"><entity charOffset="0-9" id="DDI-PubMed.23884207.s2.e0" text="Sirolimus" /><entity charOffset="49-58" id="DDI-PubMed.23884207.s2.e1" text="rapamycin" /><pair ddi="false" e1="DDI-PubMed.23884207.s2.e0" e2="DDI-PubMed.23884207.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23884207.s2.e0" e2="DDI-PubMed.23884207.s2.e1" /></sentence><sentence text=" Sirolimus has low oral bioavailability and exhibits large pharmacokinetic variability"><entity charOffset="1-10" id="DDI-PubMed.23884207.s3.e0" text="Sirolimus" /></sentence><sentence text=" The underlying mechanisms for this variability have not been explored to a large extent" /><sentence text=" Sirolimus metabolism was characterized by in vitro intrinsic clearance estimation"><entity charOffset="1-10" id="DDI-PubMed.23884207.s5.e0" text="Sirolimus" /></sentence><sentence text=" Pathway contribution ranked from CYP3A4 &gt; CYP3A5 &gt; CYP2C8" /><sentence text=" With the well stirred and Qgut models sirolimus bioavailability was predicted at 15%"><entity charOffset="39-48" id="DDI-PubMed.23884207.s7.e0" text="sirolimus" /></sentence><sentence text=" Interindividual differences in bioavailability could be attributed to variable intestinal CYP3A expression" /><sentence text=" The physiologically-based pharmacokinetics (PBPK) model developed in Simcyp predicted a high distribution of sirolimus into adipose tissue and another elimination pathway in addition to CYP-mediated metabolism"><entity charOffset="110-119" id="DDI-PubMed.23884207.s9.e0" text="sirolimus" /></sentence><sentence text=" PBPK model predictive performance was acceptable with Cmax and area under the curve (AUC) estimates within 20% of observed data in a dose escalation study" /><sentence text=" The model also showed potential to assess the impact of hepatic impairment and drug-drug interaction (DDI) on sirolimus pharmacokinetics"><entity charOffset="111-120" id="DDI-PubMed.23884207.s11.e0" text="sirolimus" /></sentence><sentence text="CPT: Pharmacometrics &amp; Systems Pharmacology (2013) 2, e59; doi:10" /><sentence text="1038/psp" /><sentence text="2013" /><sentence text="33; published online 24 July 2013" /><sentence text=" " /></document>